Turn Therapeutics (NASDAQ:TTRX) Earns Buy Rating from D. Boral Capital

Turn Therapeutics (NASDAQ:TTRX)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock. D. Boral Capital’s price objective indicates a potential upside of 72.41% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings initiated coverage on shares of Turn Therapeutics in a report on Monday, January 5th. They issued a “sell (e-)” rating for the company. D Boral Capital raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Turn Therapeutics Stock Up 0.4%

TTRX stock opened at $4.64 on Tuesday. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The stock has a market capitalization of $136.60 million and a price-to-earnings ratio of -66.29. The firm has a 50 day moving average of $3.72.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

Insider Activity at Turn Therapeutics

In related news, Director Arthur F. Golden acquired 20,532 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average price of $2.87 per share, with a total value of $58,926.84. Following the transaction, the director owned 50,734 shares of the company’s stock, valued at approximately $145,606.58. This trade represents a 67.98% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have purchased 37,850 shares of company stock valued at $117,747.

Institutional Investors Weigh In On Turn Therapeutics

A hedge fund recently bought a new stake in Turn Therapeutics stock. RVW Wealth LLC acquired a new stake in Turn Therapeutics Inc. (NASDAQ:TTRX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 18,000 shares of the company’s stock, valued at approximately $71,000. RVW Wealth LLC owned 0.06% of Turn Therapeutics at the end of the most recent quarter.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.